POSITIVE Stroke Clinical Trial
Ischemic Stroke
About this trial
This is an interventional treatment trial for Ischemic Stroke
Eligibility Criteria
Inclusion Criteria:
- Age 18 and older (i.e., candidates must have had their 18th birthday)
- NIHSS ≥8 at the time of neuroimaging
- Presenting or persistent symptoms within 6-12 hours of when groin puncture can be obtained
- Neuroimaging demonstrates large vessel proximal occlusion (distal ICA through MCA M1 bifurcation)
- The operator feels that the stroke can be appropriately treated with traditional endovascular techniques (endovascular mechanical thrombectomy without adjunctive devices such as stents)
- Pts are within 6-12 hours of symptom onset, that have received IV-tPA without improvement in symptoms are eligible for this study. Patients presenting earlier than 6 hours should be treated according to local standard of care.
- Pre-event Modified Rankin Scale score 0-1
- Consenting requirements met according to local IRB
Exclusion Criteria:
- Patient is less than 6-hours from symptom onset
- Rapidly improving neurologic examination
- Absence of large vessel occlusion on non-invasive imaging
- Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory
- Absence of an associated large penumbra as defined by physiologic imaging according to standard of practice at the participating institution
- Any intracranial hemorrhage in the last 90 days
- Known irreversible bleeding disorder
- Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 2.5 or institutionally equivalent prothrombin time of 2.5 times normal
- Platelet count < 100 x 103 cells/mm3 or known platelet dysfunction
- Inability to tolerate, clinically documented evidence in medical history of adverse reaction to, or contraindication to medications used in treatment of the stroke
- Contraindication to CT and MRI (i.e., iodine contrast allergy or other condition that prohibits imaging from either CT or MRI)
- Known allergy to contrast used in angiography that cannot be medically controlled
- Relative contraindication to angiography (e.g., serum creatinine > 2.5 mg/dL)
- Women who are currently pregnant or breast-feeding (Women of child-bearing potential must have a negative pregnancy test prior to the study procedure (either serum or urine)
- Evidence of active infection (indicated by fever at or over 99.9 °F and/or open draining wound) at the time of randomization
- Current use of cocaine or other vasoactive substance
- Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 90 days
- Patients who lack the necessary mental capacity to participate or are unwilling or unable to comply with the protocol's follow up appointment schedule (based on the investigator's judgment)
Head CT or MRI Scan Exclusion Criteria
- Presence of blood on imaging (subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), etc.)
- High density lesion consistent with hemorrhage of any degree
- Significant mass effect with midline shift
- Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on the baseline CT scan or ASPECTS of < 7; Sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment
Sites / Locations
- St. Joseph's Hospital and Medical Center
- Cedars Sinai Medical Center
- Swedish/Colorado Neurological Institute
- Baptist Health
- Rush University Medical Center
- Univesity of Massachusetts-Worcester
- Saint Luke's Hospital
- Captial Health
- University of Buffalo Neurosurgery
- Icahn School of Medicine at Mount Sinai
- Stony Brook Medical Center
- Cleveland Clinic
- Ohio Health
- Medical University of South Carolina
- Tennessee Interventional Associates
- Fort Sanders Regional Medical Center
- Methodist Healthcare - Memphis
- Vanderbilt University
- West Virginia University
- Wisconsin University
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Best medical therapy
Endovascular treatment
Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician. Standardization of medical management in both arms will occur according to the following: General medical management according to AHA/ASA guidelines Admission to monitored or intensive care unit for at least 24 hours Aggressive hypertensive-hypervolemic therapy should be used only in the case of symptomatic blood pressure fluctuations or if blood pressure drops below the normal range for the patient Antithrombotics: ASA 325 mg PO qd for 7 days (clopidogrel may be used as adjunctive therapy if indicated for cardiac disease) then per discretion of treating physician Close monitoring of BP and glucose with treatment according to AHA/ASA guidelines Follow-up imaging study required in any patient with neurologic deterioration
Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.